Back to Search
Start Over
Ustekinumab: a novel therapeutic option in Crohn's disease.
- Source :
-
Expert opinion on biological therapy [Expert Opin Biol Ther] 2016 Aug; Vol. 16 (8), pp. 1065-74. - Publication Year :
- 2016
-
Abstract
- Introduction: Although anti-tumour necrosis factor (TNF) agents have caused a paradigm shift in the management of moderate-to-severe Crohn's, they are sometimes associated with diminished or absent response in a considerable proportion of patients. Hence agents targeting pathways other than TNF are needed. Ustekinumab is a monoclonal antibody directed against the p40 subunit of IL-12 and 23.<br />Areas Covered: This manuscript summarises the available evidence on the efficacy and safety of Ustekinumab in Crohn's disease through data available from randomised controlled trials and compassionate use programs across the world.<br />Expert Opinion: Current literature strongly supports the fact that ustekinumab is clinically efficacious and reasonably safe for induction and maintenance of remission in moderate-to-severe Crohn's disease.
Details
- Language :
- English
- ISSN :
- 1744-7682
- Volume :
- 16
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Expert opinion on biological therapy
- Publication Type :
- Academic Journal
- Accession number :
- 27341173
- Full Text :
- https://doi.org/10.1080/14712598.2016.1205582